This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Immunologist Dr. Purvi Parikh of the Allergy & Asthma Network joined Cheddar News to break down long Covid, in which Covid symptoms remain up to two years after infection; a phenomenon that has so far mystified health experts.
Solid-state battery maker Factorial Energy recently raised $200 million in a Series D round led by Mercedes-Benz and Stellantis. Factorial says the funding will be used to accelerate commercial production and deployment of its solid-state battery technology, which the company says is safer, and offers up to 50% more driving range than current lithium-ion technology. Factorial also has joint development agreements (announced in late 2021) with Mercedes-Benz, Stellantis, and Hyundai, three of the top 10 global automotive manufacturers, to commercialize its batteries. Factorial CEO Siyu Huang joined Cheddar News' Closing Bell to discuss.
David Malott, founder and chief architect at AI PlanetWorks joins Cheddar News to discuss the release of its augmented reality NFTs for the metaverse called 'TERA.'
A 2021 report from UK Research and Innovation found that the shipping industry makes up at least 2.5 percent of the world's total CO2 emissions. It's a problem that energy solutions company, Leclanché, is trying to solve. Founded in 1909, the company has been developing and producing batteries for more than 100 years. Today, Leclanché's lithium-ion battery is used to electrify not just ships, but also railroad locomotives, trucks, and specialty vehicles. Cheddar News spoke with Pierre Blanc, chief technology and industrial officer of Leclanché, to discuss.
Amazon is betting that ammonia could be the fuel of the future, participating in a Series A round for the Brooklyn-based company Amogy in December. Amogy aims to de-carbonize transportation with a clean energy system that uses ammonia as a renewable fuel. Amogy is partnering with Amazon on its first commercial product - an ammonia-powered cargo-shipping vessel. Amogy CEO Seonghoon Woo joins Cheddar Climate to discuss.
Cryptocurrency is expected to become a part of our daily lives — but what sort of environmental impact does it have? As the U.S. becomes the crypto mining capital of the world, climate advocates are worried about mining companies reopening old coal plants, using massive amounts of energy, wasteful hardware, and more. Congressional Democrats led by Senator Elizabeth Warren are demanding answers from mining firms about their electricity use and waste levels. John Belizaire, CEO of Soluna Computing, joins Cheddar Climate to discuss the congressional letters, how crypto mining can become a green industry, and more.
Driver assistance monitoring systems are meant to keep the driver's eyes on the road, but according to a report from AAA, different ways of monitoring provide significantly different results. The study found that direct camera-based systems that scanned the driver's eye movements were faster and more reliable than those indirect systems that looked at steering-wheel input. Megan McKernan, the manager of automotive services for the Automobile Club of Southern California, joined Cheddar to discuss the findings. "Triple-A is recommending that automakers include both direct and indirect systems just to really prevent consumers from trying to misuse these systems," she said, noting that neither system on its own is not foolproof.
Wave Neuroscience is a neurological health tech company that specializes in clinical and at-home personalized brain stimulation technology. Erik Won, president and chief medical officer and Fred Walke, CEO, joined Cheddar's Opening Bell to discuss their company's hopes for allowing patients to identify and treat unique brain disorders while empowering them to understand their unique neurological makeups — including for the high-stress positions of professional athletes. "We have a mobile device that provides a very light stimulation that gives them a therapy that gives them confidence so there's a just knowing that they're doing something for it," said Walke. "But it also helps them get back into a rhythm. It helps their brain synchronize around certain frequencies that that we target, and it helps them really understand that they've done everything they can to get to their highest level of success."
